Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu


The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04334629
Recruitment Status : Unknown
Verified May 2020 by King's College London.
Recruitment status was:  Recruiting
First Posted : April 6, 2020
Last Update Posted : October 23, 2020
Guy's & St Thomas NHS Foundation Trust
Information provided by (Responsible Party):
King's College London

Brief Summary:
The study aims to evaluate the reduction in severity and progression of lung injury with three doses of lipid ibuprofen in patients with SARS-CoV-2 infections.

Condition or disease Intervention/treatment Phase
Coronavirus Respiratory Distress Syndrome SARS-CoV Infection Drug: Ibuprofen Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 230 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial
Actual Study Start Date : May 26, 2020
Estimated Primary Completion Date : May 25, 2021
Estimated Study Completion Date : September 25, 2021

Arm Intervention/treatment
No Intervention: Standard of care
Experimental: Standard of care plus lipid ibuprofen Drug: Ibuprofen
Lipid ibuprofen 200 mg
Other Name: Flarin

Primary Outcome Measures :
  1. Disease progression [ Time Frame: 14 days ]
    Worsening respiratory failure; defined using severity of hypoxaemia using [PaO2/FiO2 ratio OR SpO2/FiO2 ratio]

  2. Time to mechanical ventilation [ Time Frame: 14 days ]
    Time to mechanical ventilation (or need of)

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 28 days ]
  2. Reduction in proportion of patients who require ventilation [ Time Frame: 28 days ]
  3. Reduction in length of Critical Care stay [ Time Frame: 28 days ]
  4. Reduction in length of Hospital stay [ Time Frame: 28 days ]
  5. Modulation of serum pro- and anti-inflammatory cytokines [ Time Frame: 28 days ]
  6. Reduction in duration of ventilation [ Time Frame: 28 days ]
  7. Increase in ventilator-free days [ Time Frame: 28 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female patients aged 18 years and above;
  2. Hospitalised;
  3. Confirmed or suspected SARS-CoV-2 infection;
  4. National Early Warning Score (NEWS2) greater than or equal to 3 in a single parameter or NEWS2 > 5 overall;
  5. Acute hypoxemic respiratory failure: PaO2/FiO2 ratio less than or equal to 300 OR SpO2/FiO2 ratio < 315 (Kigali Modification)
  6. Provision of written informed consent by the patient OR by the patient's Legal Representative OR professional consultee.

Exclusion Criteria:

  1. Any of the following contraindications to ibuprofen:

    • A known hypersensitivity to ibuprofen or any other constituent of the medicinal product;
    • Patients who have previously shown hypersensitivity reactions (e.g. asthma, rhinitis, angioedema or urticaria) in response to aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs);
    • Patients with a history of, or existing gastrointestinal ulceration/perforation or bleeding, including that associated with NSAIDs;
    • Patients with severe hepatic failure;
    • Patients with acute renal failure;
    • Patients with severe heart failure.
  2. Participation in any other investigational drug products less than 30 days prior to study enrolment;
  3. Glasgow Coma Score < 12;
  4. Patients who cannot swallow oral capsules;
  5. Pregnant or lactating women;
  6. Any medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04334629

Layout table for location contacts
Contact: Ndaba Mazibuko, MD 02078485452
Contact: Chloe Farrell, PhD 02078485452

Layout table for location information
United Kingdom
Guy's and St Thomas' NHS Foundation Trust Recruiting
London, United Kingdom
Contact: Chloe Farrell, PhD    02078485452   
Sponsors and Collaborators
King's College London
Guy's & St Thomas NHS Foundation Trust
Layout table for investigator information
Principal Investigator: Richard Beale, MD Guy's and St Thomas' NHS Foundation Trust
Layout table for additonal information
Responsible Party: King's College London Identifier: NCT04334629    
Other Study ID Numbers: 282009
First Posted: April 6, 2020    Key Record Dates
Last Update Posted: October 23, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Severe Acute Respiratory Syndrome
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Infant, Premature, Diseases
Infant, Newborn, Diseases
Respiratory Tract Infections
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action